Advertisement

Topics

Canadian organizations collaborate to improve biosimilar adoption in cancer and inflammatory rheumatic and bowel disease

07:29 EDT 17 May 2019 | Generics and Biosimilars Initiative

With a number of biosimilars expected to launch in Canada in 2019 and beyond, Canadian organizations are collaborating to improve biosimilar adoption. Canada lags behind the European Union in terms of approval and uptake of biosimilars [1].

Original Article: Canadian organizations collaborate to improve biosimilar adoption in cancer and inflammatory rheumatic and bowel disease

NEXT ARTICLE

More From BioPortfolio on "Canadian organizations collaborate to improve biosimilar adoption in cancer and inflammatory rheumatic and bowel disease"

Advertisement
Quick Search
Advertisement
Advertisement